Case Report: Renal Cell Carcinoma, age 63, Male

Traditional Chemo Failed, Dosage, No Other Co-Factors Used, Maintenance

Fenbendazole Can Cure Cancer presents Case Studies of people who have treated their own cancers along with other articles to help understand how fenbendazole works with the goal of determining the optimal course of action to take should one decide to use fenbendazole. Previous articles covering other cancers are in the Archives link.

The following Case Report comes from a 63 yr old man with metastatic kidney cancer, that spread to his pancreas, lungs, inferior vena cava, and bone. He tried immunotherapy but it was unsuccessful and it also was not tolerated well. Given six months to live, he learned about fenbendazole. He took 222 mg for 3 consecutive days followed by 4 days off. Within 2 months of taking fenbendazole, the largest mass in the kidney was gone and the other tumors shrank considerably. By 5 months, all the tumors were gone. This Case Report was also written up in a medical journal providing more much detail.

I had Stage 4 kidney cancer that had spread to my IVC (inferior vena cava), right atrium of my heart, both lungs, pancreas, hip and spine.

In April of 2019 I was deemed terminally ill with six months to live. Last ditch treatment was immunotherapy (cabozantinib and nivolumab). I was given 3 half doses and it was determined that it became highly toxic from the treatment which caused a severe rash and colitis. Treatment was terminated.

First week of August 2019 started taking Fenbendozole (222 mg). NO vitamins, no CBD.

Second week of October 2019 MRI scans at Stanford shows my largest tumor in my left kidney was gone! All other tumors shrinking considerably!

January 2020 Stanford MRI scans show no evidence of disease (NED), all cancer gone! I’m still taking Fenbendozole 3 days on (222 mg/day) and four days off consistently. No vitamins at all.

I’m living proof of Fenbendozole treatment with no additional vitamins or substances. It doesn’t mean they won’t help but they aren’t needed to kill cancer cells either. All my records are proof positive.

In fact, my doctors at Stanford actually wrote up and published my case story (see below). I am Case #1, 63 yr old male, Renal Cell Carcinoma.

That was in September of last year (2021). I continue to take a 1 gram package (222 mg fenbendazole) for 3 days, then 4 days off, and that’s it.

Fenbendazole is extremely safe to take, even every day. I’ve never had any elevated liver enzymes.

Save you own life and don’t let doctors frighten you that fenbendazole will harm your liver. It’s just not true!

God bless and good luck.

J. C., Palo Alto CA

The following was reprinted with permission from Chiang RS, Syed AB, Wright JL, Montgomery B, Srinivas S (2021) Fenbendazole Enhancing Anti-Tumor Effect: A Case Series. Clin Oncol Case Rep 4:2

Case Presentation

Case 1

A 63-year-old Caucasian male presented with flank pain, rapid weight loss, and transient fever. Abdominal Computed Topography (CT) revealed a 3 cm left lower-pole solid renal mass. He underwent open partial nephrectomy with pathology showing pT1a highgrade clear cell Renal Cell Carcinoma (RCC). Several months later, he developed persistent left flank pain with finding of a 5.2 cm left kidney mass. Fine Needle Aspiration (FNA) biopsy redemonstrated clear cell RCC, and pazopanib 800 mg was initiated. Follow-up CT revealed a new 1.4 cm pancreatic head/body lesion, persistent left renal mass, and signs of sigmoid colitis. Given the concerns for disease progression and intolerable side effects, pazopanib was discontinued and cabozantinib was initiated. Interval Magnetic Resonance Imaging (MRI) showed stable size of recurrent left renal mass, mild decrease in 2.9 cm pancreatic head lesion, stable 1.2 cm distal pancreatic body lesion, and new 1.1 cm right posterior iliac bone lesion. Cabozantinib was ultimately discontinued due to persistent intolerable side effects. One month after discontinuation, repeat MRI showed increase in size of recurrent left renal mass, mild decrease in 2.3 cm pancreatic head lesion, stable 1.4 cm distal pancreatic body lesion, and unchanged 1.1 cm right posterior iliac bone lesion. Third-line treatment with nivolumab was initiated, and he only received three total treatments (240 mg × 3) over the course of a month due to developing severe rash and colitis. He was treated with steroids with resolution of colitis. During this time, he also started alternative therapy with fenbendazole 1 gm* three times per week at the suggestion of one of his friends with head/neck cancer.

Interval MRI imaging found near complete resolution of the previously noted left renal mass as well as decrease in pancreatic head/body and right posterior iliac spine lesions (Figure 1). Serial imaging for the past 10 months have not shown any evidence of recurrence or metastatic disease. He has continued taking fenbendazole without any reported side effects.

This Case Study is especially informative for several reasons. First, the successful use of what is shaping up to be the minimal dose of fenbendazole (222 mg) to eradicate metastatic cancer. Second, the effects were observed at two months of fenbendazole use with complete eradication of the cancer by 5 months. Third, another instance where fenbendazole by itself is effective, no other co-factors or substances appear necessary for the effect. There is the possibility of an unrecognized, latent synergistic interaction between fenbendazole and one or more of the immunotherapy drugs. However, the fact that fenbendazole alone seems to be effective in mantaining the status of no evidence of disease argues against this possibility. Four, no side effects. In fact, this person warns against being overly reactionary to the warning of potential liver damage as a reason to be wary of fenbendazole. Also, of note, is this person is 63 yrs old, previous Case Studies where liver enzymes were elevated were in the 60+ age group and they were temporary.

A working theory is that when liver enzymes using fenbendazole are elevated they are temporary, may be caused by an interaction with fenbendazole and a third factor (like fulvestrant), they may reflect stress on the liver caused by the excess cancer cell debris in the blood and the liver enzymes return to normal levels. This is not to be dismissive of the observation but merely to suggest that fluctuations in liver enzymes could be interpreted as a good sign that fenbendazole “is working.”

On a personal note, the father of one of the authors of this Substack died of the same type of kidney cancer described here several years back. One of the most frequent comments we hear in response to these Substacks is “If only I had known then what I know now…” That thought is especially poignant today.

Finally, the most important take away message here is that it is up to you to be that family friend! Every one of you reading this knows someone with cancer. Help them! Tell them about fenbendazole, send them this Substack. Be that someone’s hero.

If you would like to report your experiences with fenbendazole you can do so by email fenbendazole77@gmail.com. Also, if you know of people who’ve tried fenbendazole, and it didn’t work, we’d be especially interested in hearing from you now. Understanding the conditions and factors that impede the success of fenbendazole in curing cancer are just as valuable, maybe even more valuable, as those that facilitate its success.

*the packets are 1 gm total containing 222 mg fenbendazole.